Merit Medical (MMSI) Q2 2026 earnings review
Clean Beat-and-Raise Masking Cash Flow Deceleration
Merit Medical delivered a formidable Q2, accelerating revenue growth to 10% YoY and expanding non-GAAP operating margins by 140 basis points to 22.6%. The company successfully flexed its pricing power and product mix to absorb tariff headwinds, leading to an 18% surge in non-GAAP EPS ($1.19 vs $1.01). Management aggressively raised FY26 guidance, shifting the EPS midpoint up by a massive $0.22. However, beneath the pristine P&L, working capital is acting as a drag—Operating Cash Flow moved opposite to Net Income, driving a 14% YTD decline in Free Cash Flow.
🐂 Bull Case
Merit's 'Continued Growth Initiatives' are working flawlessly. Non-GAAP gross margins jumped 260 bps to 55.8%, signaling that the portfolio shift toward high-margin Therapeutic products is structurally elevating profitability.
Domestic sales accelerated to 11.5% constant currency growth, shrugging off the OEM destocking and supply chain fears that haunted the Q1 2026 outlook.
🐻 Bear Case
Despite Net Income soaring 27% YTD, Operating Cash Flow dropped 11%. This divergence points to a significant working capital drain, likely via bloated inventories, reducing the capital available for aggressive M&A.
While total revenue grew 10%, Foundational Procedural Solutions collapsed 12% YoY, and Renal Therapies remains trapped in negative territory, highlighting pockets of structural weakness.
⚖️ Verdict: 🟢
Bullish. The margin expansion and significant guidance upgrade far outweigh the working capital drag in the short term. Management is successfully navigating the transition toward higher-acuity, higher-margin products.
Key Themes
Therapeutic Segment Leading the Growth Narrative
The strategic re-segmentation introduced in Q1 is paying dividends by highlighting the true growth engines. Therapeutic products (disease treatment) surged 15% YoY ($137.9M), massively outpacing the 7% growth in Foundational products ($281.0M). Standouts included Endoscopy (+29%) and Cardiac Therapies (+24%), validating Merit's investments in complex, high-acuity categories.
Margin Expansion Defying Tariffs
Accelerating. Non-GAAP operating margin expanded from 21.2% in 25Q2 to 22.6% in 26Q2. This 140 basis point expansion occurred despite management previously guiding for a $15M full-year tariff headwind. Merit is successfully utilizing price pass-throughs, the DualCap divestiture, and manufacturing efficiencies to protect and grow the bottom line.
U.S. Demand Reversing Q1 Softness
Reversing. After citing U.S. customer destocking as a primary headwind for the OEM business in Q1, domestic revenue rebounded sharply, posting 11.5% constant currency growth ($252.1M). This dramatically outperformed international markets (+4.7% CC), proving that U.S. hospital demand for core products remains extremely robust.
Free Cash Flow Diverging from Net Income
Decelerating. This is the quarter's most glaring contradiction. While YTD Net Income is up 27%, YTD Free Cash Flow fell 14% to $76.6M. Operating Cash Flow decreased by $13.9M YoY despite flat Capital Expenditures. When cash flow moves opposite to earnings in a growing company, it invariably signals a rapid build-up in working capital—likely inventory stocking to support recent acquisitions or buffer against supply chain issues.
Procedural Solutions Collapse
Decelerating. Foundational Procedural Solutions revenue dropped 12% YoY to $27.9M (down 10% YTD). When a sub-segment shrinks double-digits during a double-digit corporate growth quarter, it requires immediate attention. It acts as a heavy anchor on the overall Foundational portfolio.
Renal Therapies Hangover
Stable but negative. Renal Therapies (Therapeutic segment) fell 1% in Q2 and is down 8% YTD. This persistent drag is likely a lingering effect of the Q1 Class I recall related to a supply chain issue. Management previously called it 'financially immaterial,' but consecutive quarters of contraction suggest reputational or competitive friction.
Product Innovation: OneMark and Endoscopy
The Q1 $140M acquisition of View Point Medical (OneMark Detection Imaging) and the earlier integration of the C2 CryoBalloon are actively driving the 29% surge in Endoscopy and oncology-adjacent portfolios. Management's strategy to execute 'tuck-in' M&A to immediately stuff the bags of their existing sales reps is working flawlessly.
Macro FX Drag Reabsorbed
A strong US Dollar clipped approximately 80 basis points off top-line growth ($3M impact in Q2, $10.9M YTD). Despite these geopolitical and currency headwinds—which severely hampered the OEM unit in late 2025—the total business still beat the high end of expectations.
Other KPIs
Stable. Down slightly from $34.8M in the prior year. The decline in Free Cash Flow is entirely driven by operations (working capital), not excessive capital reinvestment.
Reversing. After plunging 14% YoY in Q1 2026 due to destocking, Foundational OEM sales bounced back to grow 12% YoY in Q2. This normalization is a major relief for the baseline business.
Guidance
Accelerating. Implies ~8% YoY reported growth. Management upgraded this from the prior 6%-8% range, signaling immense confidence in H2 execution and proving that Q1's OEM hiccups were truly transient.
Accelerating. Implies 11%-14% YoY growth, a massive upward revision from the previous 5%-8% ($4.01-$4.15) guide. This proves that the View Point Medical acquisition's $0.05 dilution has been completely neutralized by operational leverage and gross margin expansion.
Key Questions
Working Capital and FCF Dynamics
With Net Income up 27% YTD but Operating Cash Flow down 11%, what specific working capital accounts are absorbing this cash? Is this defensive inventory stocking, or are there underlying collections/payable timing issues?
Procedural Solutions Decline
Foundational Procedural Solutions dropped 12% year-over-year in a quarter where total company revenue grew 10%. What is the structural issue within this specific segment, and when do you expect it to bottom out?
WRAPSODY Update
Following the reimbursement missteps highlighted in 2025, how is the WRAPSODY commercialization tracking against the $7 million internal target for 2026? Has the TPT add-on payment approval materialized as expected?
Renal Therapies Recovery
Renal Therapies is down 8% YTD. How much of this is lingering reputational damage or supply constraint from the Q1 Class I recall, and what is the timeline to return this segment to growth?